

Resolving Cancer Heterogeneity: Drawing new horizons in precision medicine



Promoted by



FONDAZIONE
INTERNAZIONALE
MENARINI

Organized by

Department of Translational Molecular Pathology
University of Texas MD Anderson Cancer Center
Houston (Texas, USA)

Department of Tumor Biology
University Medical Center Hamburg-Eppendorf
Hamburg (Germany)

**Congress Center | Trump International Hotel
Washington DC | May, 11th|13th 2017**

PROGRAM

Co-Presidents of the symposium

Ignacio I. Wistuba

*Professor and Chairman, Department of Translational Molecular Pathology
University of Texas MD Anderson Cancer Center
Houston (Texas, USA)*

Klaus Pantel

*Professor and Chairman, Department of Tumor Biology
University Medical Center Hamburg-Eppendorf
Hamburg (Germany)*

Promoted by

Fondazione Internazionale Menarini

Centro Direzionale Milanofiori
Edificio L - Strada 6
20089 Rozzano (Milan, Italy)

Phone: +39 02 55308110 - Fax: +39 02 55305739

milan@fondazione-menarini.it
www.fondazione-menarini.it

Organizing Secretariat

DueCi Promotion srl

Via C. Farini, 28
40124 Bologna (Italy)

Phone: +39 051 4841310

Fax : +39 051 247165

ggrillenzoni@duecipromotion.com

www.duecipromotion.com

Under the auspices of



PROGRAM

4:00-4:30 pm Registration

4:30-4:45 pm I. Wistuba, K. Pantel
Welcome from the Presidents

SESSION I • Chairs: N.H. Stoecklein, F. De Braud
Intra-tumor heterogeneity and genomics

4:45-5:15 pm **M.R. Wang**
Molecular alterations and intratumor heterogeneity in esophageal squamous cell carcinoma

5:15-5:45 pm **M. Snuderl**
Temporospatial heterogeneity of brain tumors

5:45-6:15 pm **J.P. Castaño**
Alternative splicing: an emergent hallmark in cancer and in tumor heterogeneity

Chairs: I. Wistuba, K. Pantel

6:15-7:00 pm **A. Futreal**
Keynote: Implications of intra-tumor heterogeneity for therapy

7:00-8:00 pm **Welcome reception**

SESSION II • Chairs: C. Alix-Panabieres, K. Pantel
Intra-tumor heterogeneity on immune response and single cell analysis

8:00-8:30 am **S. Abrignani**
Heterogeneity of intratumoral T lymphocytes

8:30-9:00 am **T. Shibata**
Inter-patient heterogeneity in tumor microenvironment

9:00-9:30 am **J. Zhang**
Intra-tumor heterogeneity of lung cancer: beyond genomics

9:30-10:00 am **R. Dolcetti**
Personalized immunotherapy to overcome cancer heterogeneity

10:00-10:30 am *Coffee break*

10:30-11:00 am **S.A. Mani**
Role of cancer cell plasticity in tumor heterogeneity

11:00-11:30 am **N.H. Stoecklein**
CTC-analysis: new insights through molecular single cell analysis

11:30-12:00 am **O. Rozenblatt-Rosen**
Dissecting the tumor ecosystem with single cell RNA-Seq

12:00-12:30 pm **G. Stanta**
Tumor heterogeneity: a complex approach for clinical research and diagnostics

12:30-2:00 pm *Lunch*

SESSION III • Chairs: I. Wistuba, A. Scarpa
 Intra-tumor heterogeneity and cancer therapy

- 2:00-2:30 pm **F. De Braud**
 Mechanism of resistance to target therapy and treatment strategy in solid tumors : focus on lung and colorectal cancer
- 2:30-3:00 pm **P. Metrakos**
 Heterogeneity in colorectal cancer metastasis and response to therapy: Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
- 3:00-3:30 pm **R. Rosell**
 Kinome reprogramming in EGFR mutant NSCLC
- 3:30-4:00 pm *Coffee break*
- 4:00-4:30 pm **C. Paoletti**
 Using liquid biopsy to detect diverse mechanisms of resistance to endocrine therapy in hormone-receptor positive metastatic breast cancer
- 4:30-5:00 pm **M. Scaltriti**
 PI3K inhibitors, how to treat and who?
- 5:00-5:30 pm **A. Scarpa**
 Cancer heterogeneity and molecular diagnostics
- 5:30 -6:00 pm **S.L. Carter**
 Computational dissection of intra-tumor genetic heterogeneity and applications to the study of cancer treatment, evolution, and metastasis

SESSION IV • Chairs: J.W. Janni, D. Marchetti
 Intra-tumor heterogeneity and liquid biopsy

- 8:30-9:00 **K. Pantel**
 Circulating tumor cells: Molecular characterization and clinical applications in patients with solid tumors
- 9:00-9:30 am **C. Alix-Panabieres**
 Molecular portrait of metastasis-competent CTCs in colon cancer
- 9:30-10:00 am **H.A. Alvarez**
 Time and space continuum of tumor evolution through Liquid Biopsies
- 10:00-10:30 am **D. Marchetti**
 Transcriptomic interrogation and biomarker heterogeneity of breast cancer CTCs associated with brain metastasis
- 10:30-11:00 am *Coffee break*
- 11:00-11:30 am **D. Rothwell**
 Utilising CTCs to investigate tumour molecular status and heterogeneity in small cell lung cancer
- 11:30-12:00 am **J.W. Janni**
 Clinical utility and perspectives of CTCs in advanced breast cancer
- 12:00-12:30 am **L. Terstappen**
 CTCs: past, present and future
- I. Wistuba, K. Pantel**
 Closing remarks
- 13:00-2:00 pm *Farewell lunch*

FACULTY

Abrignani Sergio

National Institute of Molecular Genetics "Romeo ed Enrica Invernizzi"
and Università degli Studi di Milano, Italy

Alix-Panabieres Catherine

Laboratoire Cellules Circulantes Rares Humaines (LCCRH),
Département Biopathologie Cellulaire et Tissulaire des Tumeurs,
CHRU de Montpellier, Université de Montpellier, France

Alvarez Hector A.

Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research,
The University of Texas MD Anderson Cancer Center, Houston, TX

Carter Scott L.

Harvard Chan School of Public Health
Department of Biostatistics and Computational Biology,
Dana-Farber Cancer Institute
Broad Institute, Joint Center for Cancer Precision Medicine, Boston, MA

Castaño Justo P.

IMIBIC - Maimónides Institute for Biomedical Research at Córdoba
and University of Córdoba, Spain

De Braud Filippo

Department of Oncology, Università degli Studi di Milano;
Department of Medical Oncology
IRCCS Istituto Nazionale dei Tumori di Milano, Italy

Dolcetti Riccardo

University of Queensland Diamantina Institute,
Translational Research Institute, Brisbane, Australia
CRO-National Cancer Institute, Aviano, Italy

Futreal Andrew

The University of Texas MD Anderson Cancer Center, Houston, TX

Janni Johann W.

Department of Gynecology and Obstetrics,
University Hospital Ulm, Ulm, Germany

Mani Sendurai A.

Department of Translational Molecular Pathology,
Division of Pathology/Lab Medicine,
The University of Texas MD Anderson Cancer Center, Houston, TX

Marchetti Dario

Biomarker Research Program
Institute of Academic Medicine,
Houston Methodist Research Institute, Houston, TX

Metrakos Peter

Multi-Organ Transplant Program and Hepatic, Pancreatic
and Biliary Program at McGill University Health Center,
Glen Site at the Royal Victoria Hospital, Montreal, Canada

Pantel Klaus

Department of Tumor Biology, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany

Paoletti Costanza

Department of Internal Medicine,
Division of Hematology Oncology, University of Michigan
Comprehensive Cancer Center, Ann Arbor, MI

Rosell Costa Rafael

Cancer Biology and Precision Medicine Program,
Catalan Institute of Oncology, Hospital Germans Trias i Pujol,
Badalona, Spain

Rothwell Dominic G.

Clinical and Experimental Pharmacology Group, Cancer Research UK
Manchester Institute, The University of Manchester, UK

Rozenblatt-Rosen Orit

Scientific Director, Klarman Cell Observatory,
Broad Institute of MIT and Harvard, Cambridge, MA

Scaltriti Maurizio

Department of Pathology and Human Oncology & Pathogenesis Program
Translational Science, Center for Molecular-Based Therapies,
Memorial Sloan Kettering Cancer Center, New York, NY

Scarpa Aldo

ARC-Net Research Centre
Department of Pathology, University and Hospital Trust of Verona, Italy

Shibata Tatsuhiro

Laboratory of Molecular Medicine, The Institute of Medical Science,
The University of Tokyo, Japan

Snuderl Matija

Department of Pathology, New York University, New York, NY, USA

Stanta Giorgio

Department of Medical Sciences, University of Trieste, Italy

Stoecklein Nikolas

Hendrik Experimental Surgical Oncology,
Department for General, Visceral, and Pediatric Surgery,
University Hospital and Medical Faculty of the Heinrich-Heine-University
Düsseldorf, Germany

Terstappen Leon

Medical Cell Biophysics, University of Twente, The Netherlands

Wang Ming-Rong

State Key Laboratory of Molecular Oncology, Cancer Hospital,
Peking Union Medical College,
Chinese Academy of Medical Sciences, Beijing, China

Wistuba Ignacio I.

Department of Translational Molecular Pathology,
The University of Texas MD Anderson Cancer Center, Houston, TX

Zhang Jianjun

The University of Texas MD Anderson Medical Center, Houston, TX

GENERAL INFORMATION

Meeting venue

The venue for the symposium is
Congress Center
Trump International Hotel
1100 Pennsylvania Ave NW
Washington, DC 20004 – USA

Secretariat during the meeting

The Secretariat will be open at the following times:
Thursday May 11th from 03:00 p.m. to 07:00 p.m.
Friday May 12th from 08:00 a.m. to 06:00 p.m.
Saturday May 13th from 08:00 a.m. to 03:00 p.m.

Official language

The official language of the meeting is English.
Simultaneous translation will not be provided.

Attendees' registration

The symposium is free to attend, but on line registration is required.

Please link to the organizing secretariat website:
www.duecipro.com > [Calendario Congressi](#) > [Registrazione on line](#)
On line registrations will be accepted on a first-come, first-served basis
and may be closed in advance whenever the maximum number of
participants allowed in the venue will be reached.

Registration includes

Access to scientific sessions, welcome reception,
coffee breaks, lunch, program book, certificate of attendance.

